title: [Biological therapy in women with inflammatory bowel disease during pregnancy].
abstract: The aim of this article is to objective review available research data regarding the safety of biological therapies during pregnancy and breastfeeding in women with inflammatory bowel disease. Biological therapies appear to be safe in pregnancy, as no increased risk of malformations has been demonstrated. Available clinical results suggest that the efficacy of infliximab and adalimumab in achieving clinical response and maintaining remission in pregnant patients might outweigh the theoretical risks of drug exposure to the fetus. If possible, anti-TNF therapy should be stopped by the end of the second trimester due to transplacental transfer and potential risk for the fetus. The use of infliximab and adalimumab is probably compatible with breastfeeding.
authors.forename: Jana
authors.initials: J
authors.lastname: Koželuhová
authors.forename: Karel
authors.initials: K
authors.lastname: Balihar
authors.forename: Eva
authors.initials: E
authors.lastname: Janská
authors.forename: Lucie
authors.initials: L
authors.lastname: Fremundová
authors.forename: Martin
authors.initials: M
authors.lastname: Matějovič
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001691:Biological Therapy; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000473:pathology; D000069285:Infliximab; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000473:pathology; D011295:Prenatal Care
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab